Skip to content

Group News

Aspen delivers double digit organic revenue grown in constant exchange rates

Mar 9, 2022

  Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced unaudited interim financial results for the six months ended 31 December 2021. SALIENT RESULTS Aspen reported the following salient results: Revenue from continuing operations increased by 4% (+10% in constant exchange rate (“CER”) to R19,4 billion…

Read More >>

Aspen concludes agreement to manufacture and make available an Aspen-branded COVID-19 vaccine (Aspenovax) throughout Africa

Mar 8, 2022

“With the conclusion of this agreement, our vision for Africa’s own vaccine has become a reality,” said Stephen Saad, Aspen Group Chief Executive.

Read More >>

Aspen presented with 2022 Economic Diplomacy (Global) Ubuntu Award

Feb 12, 2022

Cape Town, South Africa – JSE Limited-listed Aspen Pharmacare (APN), a global multinational specialty pharmaceutical company, has been presented with the South African Government and Department of International Relations and Cooperations’ (“DIRCO”) Ubuntu Award in the Economic Diplomacy (Global) category at its prestigious 6th annual awards ceremony hosted in Cape Town for this purpose. This…

Read More >>

Aspen confirms non-binding term sheet on manufacture and sale of an Aspen- branded COVID-19 vaccine throughout Africa

Nov 30, 2021

Durban, South Africa – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to confirm that one of its wholly-owned South African subsidiaries, Aspen SA Operations (Pty) Limited (“Aspen SA”), has confirmed a non-binding term sheet with Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen…

Read More >>

Aspen welcomes Kenyan President Uhuru Kenyatta to its Gqeberha manufacturing site

Nov 24, 2021

Gqeberha, South Africa – Aspen, a global multinational specialty pharmaceutical company, earlier today welcomed Kenyan President, His Excellency President Uhuru Kenyatta, to its world class flagship manufacturing site in Gqeberha. President Kenyatta’s visit to Aspen forms part of a broader collaboration and deepening of ties between South Africa and Kenya to lessen Africa’s dependence on…

Read More >>

Minister Ebrahim Patel opens Aspen’s world class general anaesthetic manufacturing line

Oct 25, 2021

Gqeberha, South Africa – Aspen, a global multinational specialty pharmaceutical company, earlier today hosted the Honorable Minister of Trade, Industry and Competition, Mr Ebrahim Patel who officially opened Aspen’s world class general anaesthetics production line at its Gqeberha-based flagship manufacturing site. This manufacturing capability will convert Aspen’s Gqeberha facility into one of the largest manufacturing…

Read More >>

Aspen increases revenue from continuing operations by 12% to R37,8 billion

Sep 1, 2021

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to report the following salient financial results for the year ended 30 June 2021: Revenue from continuing operations increased by 12% to R37,8 billion (June 2020: R33,7 billion*); Normalised EBITDA from continuing operations increased by 3% to…

Read More >>

Stephen Saad discusses the J&J vaccine release with eNCA’s Sally Burdett

Jul 27, 2021

Aspen confirmed on 26 July 2021 that the first supplies to South Africa of the Johnson & Johnson COVID-19 vaccines, from the new API source located in Europe, were being released to Johnson & Johnson from its flagship Gqeberha-based manufacturing site. These vaccines will be further distributed throughout South Africa in line with the various…

Read More >>

Aspen confirms release of Covid-19 vaccines to Johnson & Johnson for supply to South Africa

Jul 26, 2021

Durban, South Africa – Aspen, a global multinational specialty pharmaceutical company, is pleased to confirm that the first supplies to South Africa of the Johnson & Johnson COVID-19 vaccines, from the new API source located in Europe, will be released to Johnson & Johnson from its flagship Gqeberha-based manufacturing site later today. These vaccines will…

Read More >>

CNN Live – Aspen’s US$700m investment in equitable vaccine access for Africa

Jul 8, 2021

“Over 90% of our vaccines are imported. A high majority from #India. When India cut off all exports, #Africa was left without vaccines.” Stephen Saad, CEO @aspenpharma discusses their recent $700M investment & ensuring future Africa supplies.

Read More >>

CONTACT DETAILS

Shauneen Beukes
Group Communications Manager
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com

Scroll To Top